rf-fullcolor.png

 

June 16, 2017
by Zachary Brennan

WHO to Craft Essential Diagnostics List

The World Health Organization (WHO) has received a recommendation from an expert committee to develop an Essential Diagnostics List (EDL).

The committee said the decision to begin developing such a list, agreed to earlier this month, may initially focus on in vitro diagnostics, with initial proposed priority areas including tuberculosis, malaria, HIV and hepatitis B and C.

According to WHO, the list "should expand to other areas including other antimicrobials and non-communicable diseases as soon as possible."

As a first step, WHO is creating a Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD), which will advise on policies and the development of the list.

Like its Essential Medicines List, WHO says the EDL is intended to provide countries with evidence-based guidance to create their own national lists of essential diagnostic tests and tools.

"National essential medicines lists have been successful in facilitating access to treatment and promoting affordable prices, particularly in low-resourced countries, by prioritizing the most important medicines all countries need to make available to their populations. It is expected that national essential diagnostics lists will provide the same benefits for diagnostic tests," WHO said.

The Global Health Technologies Coalition welcomed what it called "a landmark decision" to guide governments on the vital diagnostic tools that should be made available through healthcare systems.

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.